Asieris Pharmaceuticals, located in Taizhou City and also known as Jiangsu Yahong, presented positive preliminary results from its ongoing Phase II clinical trial of APL-1202, an oral MetAP2 inhibitor, in patients with bladder cancer. Asieris is focused on making breakthroughs in cancer treatment by repurposing available drugs. APL-1202 is nitroxoline, a wide spectrum antibiotic with an anti-angiogenesis effect that has been used in several countries for about fifty years. Asieris presented the results at the European Association of Urology (EAU) 2016 Congress in Munich, Germany.
